Constructive Bio secures $15m in seed funding to advance synthetic biology platforms
The seed round was led by Ahren to commercialise research from the Medical Research Council.
≈ £12.4M at $1 = £0.8268 on 16 Aug 2022
Constructive Bio is a synthetic genomics startup that rewrites genomes to build novel biomolecules and sustainable materials. The company originated as a spinout from the University of Cambridge.
Constructive Bio has secured $15m in seed funding to advance its synthetic biology research and commercialise technology developed at the Medical Research Council. The round was led by Ahren, with participation from Amadeus Capital Partners, General Inception, and OMX Ventures.
The capital will be deployed to expand technology platforms, assemble synthetic genomes, and synthesise non-natural polymers using bacterial strains. The funding also supports the scaling of research originating from Professor Jason Chin's laboratory at the MRC Laboratory of Molecular Biology.
The company operates as an MRC spin-out, holding an exclusive licence to intellectual property aimed at enabling novel therapeutics, enhanced agriculture, and advanced manufacturing materials.
From the founder
"I am pleased that we have attracted significant support and seed funding to establish Constructive Bio and capture this opportunity. By taking inspiration from nature and reimagining what life can become we have the opportunity to build the sustainable industries of the future."
Jason Chin
CSO at Constructive Bio
Investor perspective
"We look forward to working with the company, its commercial partners, the MRC, and our co-investors, all of whom have provided key contributions, to deliver on this substantial opportunity over the coming years."
Matthew Newcombe-Ellis
Operating Partner, Ahren
Use of funds
- 01Continue product development
- 02Fund research and development
Investors
About the company
Constructive Bio
Constructive Bio rewrites genomes to turn living cells into sustainable biofactories.